ULBP1 and acute myeloid leukemia: In the case of acute myeloid leukemia (AML), the expression of the NKG2D ligand ULBP1 on AML blasts may be a predictive biomarker for efficacy.233 Conversely, off-the-shelf produced GMP-expanded γδ T cell products generated from different blood donors might not be equally effective against various tumor entities.